Robert Blum, Cytokinetics CEO

Cy­to­ki­net­ics lifts cur­tain on Phase 3 afi­camten da­ta, com­mer­cial launch prep un­der­way

Cy­to­ki­net­ics de­tailed re­sults on Mon­day from a late-stage tri­al of afi­camten for a rare heart dis­ease, and the com­pa­ny is al­ready hir­ing med­ical af­fairs and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.